Advertisement

Future Directions in Reconstructive and Regenerative Surgery

  • Giorgio Giatsidis
Chapter

Abstract

Over the last 5 years, major biomedical, technological, and manufacturing advances have helped reshape the therapeutic potential of gene therapies and facilitate their translation to clinical care. This chapter aims to provide brief insights on some of the innovations that are impacting the field, the CRISPR/Cas9 system and the therapeutic use of micro-RNAs are worth mentioning.

References

  1. 1.
    McNutt M. Breakthrough to genome editing. Science. 2015;350(6267):1445.  https://doi.org/10.1126/science.aae0479.CrossRefPubMedGoogle Scholar
  2. 2.
    Pineda M, Moghadam F, Ebrahimkhani MR, Kiani S. Engineered CRISPR systems for next generation gene therapies. ACS Synth Biol. 2017;6(9):1614–26.  https://doi.org/10.1021/acssynbio.7b00011.CrossRefPubMedGoogle Scholar
  3. 3.
    Wang HX, Li M, Lee CM, et al. CRISPR/Cas9-based genome editing for disease modeling and therapy: challenges and opportunities for nonviral delivery. Chem Rev. 2017;117(15):9874–906.  https://doi.org/10.1021/acs.chemrev.6b00799.CrossRefPubMedGoogle Scholar
  4. 4.
    Puga Yung GL, Rieben R, Bühler L, Schuurman H-J, Seebach J. Xenotransplantation: where do we stand in 2016? Swiss Med Wkly. 2017;147(506):w14403.  https://doi.org/10.4414/smw.2017.14403.CrossRefPubMedGoogle Scholar
  5. 5.
    Feng W, Dai Y, Mou L, Cooper D, Shi D, Cai Z. The potential of the combination of CRISPR/Cas9 and pluripotent stem cells to provide human organs from chimaeric pigs. Int J Mol Sci. 2015;16(3):6545–56.  https://doi.org/10.3390/ijms16036545.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Butler JR, Wang Z-Y, Martens GR, et al. Modified glycan models of pig-to-human xenotransplantation do not enhance the human-anti-pig T cell response. Transpl Immunol. 2016;35:47–51.  https://doi.org/10.1016/j.trim.2016.02.001.CrossRefPubMedGoogle Scholar
  7. 7.
    Duncan KM, Mukherjee K, Cornell RA, Liao EC. Zebrafish models of orofacial clefts. Dev Dyn. 2017;246(11):897–914.  https://doi.org/10.1002/dvdy.24566.CrossRefPubMedGoogle Scholar
  8. 8.
    Hainzl S, Peking P, Kocher T, et al. COL7A1 editing via CRISPR/Cas9 in recessive dystrophic epidermolysis bullosa. Mol Ther. 2017;25(11):2573–84.  https://doi.org/10.1016/j.ymthe.2017.07.005.CrossRefPubMedGoogle Scholar
  9. 9.
    Mofazzal Jahromi MA, Sahandi Zangabad P, Moosavi Basri SM, et al. Nanomedicine and advanced technologies for burns: preventing infection and facilitating wound healing. Adv Drug Deliv Rev. 2018;123:33–64.  https://doi.org/10.1016/j.addr.2017.08.001.CrossRefPubMedGoogle Scholar
  10. 10.
    Meng Z, Zhou D, Gao Y, Zeng M, Wang W. miRNA delivery for skin wound healing. Adv Drug Deliv Rev. 2017.  https://doi.org/10.1016/j.addr.2017.12.011.
  11. 11.
    Santulli G. microRNA: medical evidence, Advances in experimental medicine and biology, vol. 888. Cham: Springer; 2015.  https://doi.org/10.1007/978-3-319-22671-2.CrossRefGoogle Scholar
  12. 12.
    Wu YF, Mao WF, Zhou YL, Wang XT, Liu PY, Tang JB. Adeno-associated virus-2-mediated TGF-β1 microRNA transfection inhibits adhesion formation after digital flexor tendon injury. Gene Ther. 2016;23(2):167–75.  https://doi.org/10.1038/gt.2015.97.CrossRefPubMedGoogle Scholar
  13. 13.
    Icli B, Nabzdyk CS, Lujan-Hernandez J, et al. Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a. J Mol Cell Cardiol. 2016;91:151–9.  https://doi.org/10.1016/j.yjmcc.2016.01.007.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Chang K-P, Lee H-C, Huang S-H, Lee S-S, Lai C-S, Lin S-D. MicroRNA signatures in ischemia-reperfusion injury. Ann Plast Surg. 2012;69(6):668–71.  https://doi.org/10.1097/SAP.0b013e3182742c45.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Plastic Surgery, Department of Surgery, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA

Personalised recommendations